SCHEMBL793883

SCHEMBL793883

CCCCN1CCN(CCOC)CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GNAI3 P08754 2/20 0.45
GNAO1 P09471 2/20 0.45
GNAI1 P63096 2/20 0.45
DRD2 P14416 3/20 0.45
DRD3 P35462 3/20 0.45
MAPK1 P28482 2/20 0.41
HTR2A P28223 2/20 0.41
SIGMAR1 Q99720 2/20 0.41
LTA4H P09960 1/20 0.41
ALDH1A1 P00352 1/20 0.41
CYP1A2 P05177 1/20 0.41
CHRM2 P08172 1/20 0.41
CHRM1 P11229 1/20 0.41
SCN1A P35498 1/20 0.41
HTR2B P41595 1/20 0.41
KCNH2 Q12809 1/20 0.41
SCN2A Q99250 1/20 0.41
SCN3A Q9NY46 1/20 0.41
HRH3 Q9Y5N1 1/20 0.41
HTR1A P08908 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25135123 1.00 GNAI3 (0.45) GNAI3GNAO1GNAI1DRD2DRD3
SCHEMBL793522 0.93 GNAI3 (0.53) GNAI3GNAO1GNAI1DRD2DRD3
SCHEMBL19634480 0.91 GNAI3 (0.57) GNAI3GNAO1GNAI1SIGMAR1LTA4H
SCHEMBL23471206 0.91 GNAI3 (0.57) GNAI3GNAO1GNAI1SIGMAR1LTA4H
SCHEMBL21367100 0.91 GNAI3 (0.45) GNAI3GNAO1GNAI1DRD2DRD3
SCHEMBL19634651 0.90 GNAI3 (0.41) GNAI3GNAO1GNAI1DRD2DRD3
SCHEMBL19634476 0.88 GNAI3 (0.44) GNAI3GNAO1GNAI1DRD2DRD3
SCHEMBL21477161 0.87 GNAI3 (0.52) GNAI3GNAO1GNAI1DRD2DRD3
SCHEMBL21303867 0.87 GNAI3 (0.52) GNAI3GNAO1GNAI1DRD2DRD3
SCHEMBL21016223 0.86 GNAI3 (0.47) GNAI3GNAO1GNAI1LTA4HALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024020221-A1 MODULATORS OF TYK2 PROTEOLYSIS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. (US) 2024-01-25 WO disclosed
EP-4310083-A1 FURAN FUSED RING-SUBSTITUTED GLUTARIMIDE COMPOUND Medshine Discovery Inc. (CN) 2024-01-24 EP disclosed
WO-2023096987-A1 BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. (US) 2023-06-01 WO disclosed
EP-4122925-A1 PROTEOLYSIS REGULATOR AND METHOD FOR USING SAME Medshine Discovery Inc. (CN) 2023-01-25 EP disclosed
WO-2021194879-A1 INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. (US) 2021-09-30 WO disclosed
EP-3831841-A1 NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF S&T Global Inc. (US) 2021-06-09 EP disclosed
WO-2021047584-A1 SUBSTITUTED (2-AZABICYCLO [3.1.0] HEXAN-2-YL) PYRAZOLO [1, 5-a] PYRIMIDINE AND IMIDAZO [1, 2-b] PYRIDAZINE COMPOUNDS AS TRK KINASES INHIBITORS FOCHON PHARMACEUTICALS, LTD. (CN) 2021-03-18 WO disclosed
US-9290503-B2 Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders CHEMBRIDGE CORPORATION (US) 2016-03-22 US disclosed
US-9273055-B2 Tyrosine kinase inhibitors CHEMBRIDGE CORPORATION (US) 2016-03-01 US disclosed
US-9249147-B2 Tyrosine kinase inhibitors CHEMBRIDGE CORPORATION (US) 2016-02-02 US disclosed
US-20110306609-A1 THIAZOLOPYRIDINE SIRTUIN MODULATING COMPOUNDS SIRTRIS PHARMACEUTICALS, INC., 2011-12-15 US disclosed
WO-2010071853-A1 THIAZOLOPYRIDINE SIRTUIN MODULATING COMPOUNDS SIRTRIS PHARMACEUTICALS, INC. (US) 2010-06-24 WO disclosed
WO-2009117097-A1 NOVEL TYROSINE KINASE INHIBITORS CHEMBRIDGE CORPORATION (US) 2009-09-24 WO disclosed
US-20080171769-A1 Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders CHEMBRIDGE CORPORATION 2008-07-17 US disclosed
WO-2008021369-A2 TRICYCLIC COMPOUNDS AND ITS USE AS TYROSINE KINASE MODULATORS CHEMBRIDGE RESEARCH LABORATORIES, INC. (US) 2008-02-21 WO disclosed
US-7241763-B2 3-furanyl analogs of toxoflavine as kinase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2007-07-10 US disclosed
EP-0154669-A1 Catalyst for urethane foam blown with carboxylic acids ABBOTT LABORATORIES (US) 1985-09-18 EP disclosed
EP-0144573-A2 Catalyst system for the production of polyurethanes AIR PRODUCTS AND CHEMICALS, INC. (US) 1985-06-19 EP disclosed
US-4500654-A N-SUBSTITUTED ALKOXYALKYL PIPERAZINE ABBOTT LABORATORIES (US) 1985-02-19 US disclosed
US-4473666-A A DIALKYLCYCLOHEXYLAMINE AND AN N-SUBSTITUTED ALKOXYALKYL PIPERAZINE ABBOTT LABORATORIES (US) 1984-09-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080171769-A1 Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders MALT1, TPMT, TSLP GNAI3 1569/4885GNAO1 2200/4885GNAI1 1027/4885
US-20110306609-A1 THIAZOLOPYRIDINE SIRTUIN MODULATING COMPOUNDS SIRT1, SIRT3, SIRT2 GNAI3 2210/4885GNAO1 1929/4885GNAI1 1493/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.